|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Factor concentrates, specifically prothrombin complex concentrates (PCCs), are often used as part of multimodal therapy for bleeding along with laboratory testing to rapidly assess underlying coagulopathy.
|
31537028 |
2020 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Rats subjected to polytrauma and hemorrhage develop a coagulopathy that is similar to acute coagulopathy of trauma in humans, and is associated with a rise in prothrombin time and a fall in clot strength.
|
31090681 |
2020 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The patient's presumed AMR, cardiogenic shock, and coagulopathy were treated with extracorporeal membrane oxygenation (ECMO), plasmapheresis, intravenous immunoglobulin (IVIG), multiple blood products, and prothrombin complex concentrate.
|
31400258 |
2020 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Neither the presence of ascites (6.6% complications) nor of coagulopathy (platelets<50G/L and/or prothrombin time<50%; 4.8% complications) increased the risk for complications.
|
30862438 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In conjunction with routine diagnostics for injury and disease, we performed two blood clotting assays (prothrombin time, Russell's viper venom time) affected by vitamin K-dependent coagulopathy of samples from six species of live raptors admitted to a rehabilitation facility.
|
30677887 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Prothrombin, alone or in complex concentrates or plasma, reduces bleeding in a mouse model of blood exchange-induced coagulopathy.
|
31506556 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We present a case of a 15-month-old female infant with type I biliary atresia with jaundice (total serum bilirubin, 22.2 mg/dL), hypoalbuminemia (serum albumin level, 2.58 g/dL), coagulopathy (prothrombin time > 20 s compared with that of a normal control), ascites, splenomegaly, portal hypertension (portal vein velocity, 3.9-5.6 cm/sec of hepatopetal flow), and repeated bleeding of the varices after receiving three doses of intravascularly administered Histoacryl 1 ampoule mixed with Lipiodol UF 8 mL in the EV.
|
30819091 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Coagulopathy due to warfarin in patients with major bleeding was traditionally reversed with fresh frozen plasma and intravenous (IV) vitamin K, but prothrombin complex concentrates (PCC) are increasingly used in the treatment of these patients.
|
31176578 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Tigecycline-induced coagulopathy usually manifests as the dose-dependent prolongation of prothrombin time and activated partial thromboplastin time and a reduction in the fibrinogen level.
|
31713108 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The objective of this study was to analyse the effect of the temperature and the storage of plasma sample on Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) in clinical samples for 65 patients without coagulation disorders.
|
30868948 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Intravenous (IV) prothrombin complex concentrate (PCC) may reverse VKA-induced coagulopathy in <30 min.
|
31060844 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
They have demonstrated that a prothrombin defect may be associated with thrombosis, that a mild bleeding tendency may occur despite normal Factor V levels and that high levels of plasmatic thrombomodulin may be associated with mild bleeding.
|
31793409 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The haemostatic effect of 2, 4 and 8 mg/kg recombinant prothrombin (MEDI8111) co-administered with 100 mg/kg fibrinogen (n = 7-8) was investigated in a porcine model of dilutional coagulopathy with uncontrolled bleeding.
|
31090596 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
On admission, laboratory assays showed severe coagulopathy of unknown cause; the patient was empirically treated using a multimodal hemostatic approach with prothrombin complex concentrate, fresh-frozen plasma, and tranexamic acid.
|
30964547 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The deficiency of fibrinogen, prothrombin, factor V (FV), FVII, FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathies leading to spontaneous or posttrauma and postsurgery hemorrhages.
|
30559262 |
2019 |
|
Blood Coagulation Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Prothrombin time and activated partial thromboplastin time were slightly prolonged in 10 patients (7.1%) because of mild coagulation factor deficiencies, which were not responsible for the bleeding diathesis. von Willebrand factor antigen, ristocetin cofactor, endogenous thrombin potential and platelet count were normal in all patients.
|
30312027 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Utility of prothrombin complex concentrate as first-line treatment modality of coagulopathy in patients undergoing liver transplantation: A propensity score-matched study.
|
30375084 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We defined coagulopathy as EXTEM clot amplitude at 5 min (A5) < 40 mm or prothrombin ratio > 1.5.
|
29743045 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We assessed the performance of prothrombin time (PT) at point-of-care in trauma patients to detect moderate and severe coagulopathy on admission.
|
29707780 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Prothrombin complex concentrate (PCC) is increasingly used to correct acquired coagulopathy in trauma and surgery.
|
30236256 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
This dogma was seemingly supported by abnormalities in standard laboratory tests (SLTs), such as the prothrombin time, that were interpreted as indicating a bleeding diathesis.
|
29027774 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The rare congenital bleeding disorders are a heterogeneous group of diseases which include deficiencies of fibrinogen, prothrombin and factors V, V + VIII, VII, X, XI and XIII.
|
30306070 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The patients were classified in the clinically unstable group if at least 1 of the following conditions was observed upon admission in the ED: hypoxia requiring oxygen supplementation, hypotension requiring inotropic support, coagulopathy with prothrombin time (international normalized ratio, ≥1.5), and seizures or altered consciousness.
|
29794953 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis.
|
29664892 |
2018 |
|
Blood Coagulation Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma.
|
29661410 |
2018 |